Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

January 26, 2016

(Exact name of registrant as specified in its charter)



New Jersey	I-3215	22-1024240
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:

732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17

CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17

CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On January 26, 2016, Johnson & Johnson issued the attached press release announcing its sales and earnings for the fourth quarter ended January 3, 2016.

Item 9.01 Financial Statements and Exhibits



Exhibit No.	Description of Exhibit
99.15	Press Release dated January 26, 2016 for the period ended January 3, 2016.
99.2O	Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fourth quarter and full year.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



	Johnson & Johnson
		(Registrant)
Date: January 26, 2016	By:	/s/ Ronald A. Kapusta
		Ronald A. Kapusta Controller (Principal Accounting Officer)

Exhibit 99.15

Johnson & Johnson Reports 2015 Fourth-Quarter Results:

2015 Fourth-Quarter Sales of $17.8 Billion decreased 2.4%; EPS was $1.15

2015 Full-Year Sales of $70.1 Billion decreased 5.7%, Full-Year EPS was $5.48

Adjusted 2015 Fourth-Quarter EPS was $1.44, an increase of 5.1%*, and Adjusted 2015 Full-Year EPS was $6.20, a decrease of 3.0%*

Strong Operational Sales Growth

Excluding Acquisitions/Divestitures and Hepatitis C Impact

New Brunswick, N.J. (January 26, 2016) - Johnson & Johnson (NYSE: JNJ) today announced sales of $17.8 billion for the fourth quarter of 2015, a decrease of 2.4% as compared to the fourth quarter of 2014. Operational sales results increased 4.4% and the negative impact of currency was 6.8%. Domestic sales increased 8.0%. International sales decreased 11.7%, reflecting operational growth of 1.2% and a negative currency impact of 12.9%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 7.8%, domestic sales increased 13.4% and international sales increased 2.9%.^*

Worldwide sales for the full-year 2015 were $70.1 billion, a decrease of 5.7% versus 2014. Operational results increased 1.8% and the negative impact of currency was 7.5%. Domestic sales increased 2.6%. International sales decreased 13.1%, reflecting operational growth of 1.1% and a negative currency impact of 14.2%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 6.5%, domestic sales increased 10.6% and international sales increased 3.0%.^*

Net earnings and diluted earnings per share for the fourth quarter of 2015 were $3.2 billion and $1.15, respectively. Fourth-quarter 2015 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.6 billion. Fourth-quarter 2014 net earnings included after-tax intangible amortization expense of approximately $0.3 billion and a charge for after-tax special items of approximately $1.1 billion. A reconciliation of non-GAAP financial measures is included as an accompanying schedule. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.0 billion and adjusted diluted earnings per share were $1.44, representing increases of 4.0% and 5.1%, respectively, as compared to the same period in 2014.^* On an operational basis, adjusted diluted earnings per share increased 12.4%.^*

Net earnings and diluted earnings per share for the full-year 2015 were $15.4 billion and $5.48, respectively. Full-year net earnings included after-tax intangible amortization expense of approximately $1.1 billion and a net charge for after-tax special items of approximately $0.9 billion. Full-year 2014 net earnings included after-tax intangible amortization expense of approximately $1.2 billion and a net charge for after-tax special items of approximately $0.8 billion. A reconciliation of non-GAAP financial measures is included as an accompanying schedule. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the full-year of 2015 were $17.4 billion and adjusted diluted earnings per share were $6.20, representing decreases of 4.8% and 3.0%, respectively, as compared to the full year of 2014.^* On an operational basis, adjusted diluted earnings per share increased 5.8%.^*

"Johnson & Johnson delivered strong underlying growth in 2015, driven by the performance of our Pharmaceutical business and iconic Consumer brands,” said Alex Gorsky, Chairman and Chief Executive Officer. “As we enter 2016, our core business is very healthy, and the recent decisive actions we’ve taken in support of each of our businesses position us well to drive sustainable long-term growth, faster than the markets we compete in.”

Mr. Gorsky continued, “I want to thank all of our colleagues for contributing to these results through their commitment and dedication to the people around the world who rely on our products.”

The company announced its 2016 full-year guidance for sales of $70.8 billion to $71.5 billion reflecting expected operational growth in the range of 2.5% to 3.5%. Excluding the impact of acquisitions, divestitures and hepatitis C sales, operational sales growth is expected to be in the range of 4.5% to 6.0%.* Additionally, the company announced adjusted earnings guidance for full-year 2016 of $6.43 to $6.58 per share reflecting expected operational growth in the range of 5.3% to 7.7%.* Adjusted earnings guidance excludes the impact of after-tax intangible amortization expense and special items.

Worldwide Consumer sales of $13.5 billion for the full-year 2015 represented a decrease of 6.8% versus the prior year, consisting of an operational increase of 2.7% and a negative impact from currency of 9.5%. Domestic sales increased 2.5%; international sales decreased 11.9%, which reflected an operational increase of 2.7% and a negative currency impact of 14.6%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 4.1%, domestic sales increased 4.6% and international sales increased 3.8%.^*

Positive contributors to Consumer operational results were sales of over-the-counter products including TYLENOL^® and MOTRIN^® analgesics, upper respiratory products including ZYRTEC^® allergy medications, and digestive health products; international feminine protection products; LISTERINE^® oral care products; and NEUTROGENA^® skin care products.

Worldwide Pharmaceutical sales of $31.4 billion for the full-year 2015 represented a decrease of 2.7% versus the prior year with an operational increase of 4.2% and a negative impact from currency of 6.9%. Domestic sales increased 5.2%; international sales decreased 12.0%, which reflected an operational increase of 3.0% and a negative currency impact of 15.0%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 11.0%, domestic sales increased 18.1% and international sales increased 3.3%.^*

Worldwide operational sales growth was driven by new products and the strength of core products. New product sales growth was negatively impacted by lower sales of OLYSIO^®/SOVRIAD^®(simeprevir) due to competitive entrants. Strong growth in new products include INVOKANA^®/INVOKAMET^®(canagliflozin), for the treatment of adults with type 2 diabetes; IMBRUVICA^® (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers; XARELTO^® (rivaroxaban), an oral anticoagulant; and ZYTIGA^® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.

Additional contributors to operational sales growth were STELARA^® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; INVEGA^®SUSTENNA^®/XEPLION^®/TRINZA^® (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults; CONCERTA^®(methylphenidate HCI), for the treatment of attention deficit hyperactivity disorder; and SIMPONI^®/SIMPONI ARIA^® (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases.

During the quarter, the U.S. Food and Drug Administration (FDA) approved DARZALEX™ (daratumumab) for the treatment of double refractory multiple myeloma. Additionally, the FDA approved YONDELIS^® (trabectedin) for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma. The European Commission approved EDURANT^® (rilpiravine) in combination with other anti-retroviral agents, for treatment-naïve adolescent patients aged 12 to 18 years with human immunodeficiency virus-1 (HIV-1) infection.

In the U.S., a New Drug Application (NDA) was submitted for INVOKAMET^® XR, a once-daily therapy combining fixed doses of canagliflozin and metformin hydrochloride extended release for the treatment of adults with type 2 diabetes. Additionally, regulatory applications were submitted for STELARA^® (ustekinumab) for the treatment of adult patients with moderately to severely active Crohn's disease to the FDA and the European Medicines Agency (EMA). Several regulatory submissions were completed for additional indications of IMBRUVICA^® (ibrutinib) including for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma in combination with bendamustine and rituximab in both the U.S. and the European Union (EU) as well as for use in treatment-naïve patients with CLL and relapsed/refractory patients with mantle cell lymphoma in the EU.

Also in the quarter, the acquisition of Novira Therapeutics, Inc., a privately held clinical-stage biopharmaceutical company developing innovative therapies for curative treatment of chronic hepatitis B virus infection, was completed.

Worldwide Medical Devices sales of $25.1 billion for the full-year represented a decrease of 8.7% versus the prior year consisting of an operational decrease of 1.4% and a negative currency impact of 7.3%. Domestic sales decreased 1.0%; international sales decreased 14.8%, which reflected an operational decrease of 1.7% and a negative currency impact of 13.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 2.5%, domestic sales increased 3.3% and international sales increased 2.0%.^*

Primary contributors to operational growth were sales of endocutters and biosurgical products in the Advanced Surgery business; electrophysiology products in the Cardiovascular business; joint reconstruction products in the Orthopaedics business; and insulin pump products in the Diabetes Care business.

During the quarter, the pediatric indication for the Animas^® Vibe^® insulin pump was approved by the FDA. Also in the quarter, the acquisition of Coherex Medical, Inc., a privately held medical device company focused on the development of the Coherex WaveCrest^® left atrial appendage occlusion system, was completed.

Subsequent to the quarter, the company announced on January 19^th, a restructuring of certain Medical Devices businesses. The company’s Consumer Medical Devices businesses, Vision Care and Diabetes Care, are not impacted by these actions. The restructuring is being undertaken to accelerate the pace of innovation, address unmet patient

needs and drive growth. The actions are expected to result in ongoing annualized, pre-tax cost savings of $0.8 billion to $1.0 billion, the majority of which is expected to be realized by the end of 2018, including approximately $200 million in 2016.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 127,000 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

^* Operational sales growth excluding the net impact of acquisitions, divestitures and hepatitis C sales, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company’s website at www.investor.jnj.com.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can be found on the company's website at www.investor.jnj.com.

NOTE TO INVESTORS

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position, business strategy and restructuring plans. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges and uncertainties inherent in new product development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; impact of business combinations and divestitures; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; any required consultation procedures relating to the restructuring workforce actions; the potential that the expected benefits and opportunities related to the restructuring may not be realized or may take longer to realize than expected; market conditions and the possibility that the on-going share repurchase program may be suspended or discontinued; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; increased scrutiny of the health care industry by government agencies; and the potential failure to meet obligations in compliance agreements with government bodies. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.

Exhibit 99.2O



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	FOURTH QUARTER

	2015			2014			Percent
			Percent			Percent	Increase
	Amount		to Sales	Amount		to Sales	(Decrease)
Sales to customers	$ 17,811		100.0	$ 18,254		100.0	(2.4)
Cost of products sold	5,673		31.8	5,853		32.1	(3.1)
Selling, marketing and administrative expenses	5,891		33.1	5,822		31.9	1.2
Research and development expense	2,864		16.1	2,635		14.4	8.7
In-process research and development	214		1.2	156		0.8
Interest (income) expense, net	107		0.6	122		0.7
Other (income) expense, net	(1,205)		(6.8)	963		5.3
Restructuring	509		2.9	—		—
Earnings before provision for taxes on income	3,758		21.1	2,703		14.8	39.0
Provision for taxes on income	543		3.0	182		1.0
Net earnings	$ 3,215		18.1	$ 2,521		13.8	27.5

Net earnings per share (Diluted)	$ 1.15			$ 0.89			29.2

Average shares outstanding (Diluted)	2,803.3			2,845.3

Effective tax rate	14.4	%		6.7	%

Adjusted earnings before provision for taxes and net earnings ^{(1) (A)}
Earnings before provision for taxes on income	$ 4,913		27.6	$ 4,296		23.5	14.4
Net earnings	$ 4,043		22.7	$ 3,887		21.3	4.0
Net earnings per share (Diluted)	$ 1.44			$ 1.37			5.1
Effective tax rate	17.7	%		9.5	%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, the Ortho-Clinical Diagnostics divestiture, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	TWELVE MONTHS

	2015			2014			Percent
			Percent			Percent	Increase
	Amount		to Sales	Amount		to Sales	(Decrease)
Sales to customers	$ 70,074		100.0	$ 74,331		100.0	(5.7)
Cost of products sold	21,536		30.7	22,746		30.6	(5.3)
Selling, marketing and administrative expenses	21,203		30.3	21,954		29.5	(3.4)
Research and development expense	9,046		12.9	8,494		11.4	6.5
In-process research and development	224		0.3	178		0.3
Interest (income) expense, net	424		0.6	466		0.6
Other (income) expense, net	(2,064)		(2.9)	(70)		(0.1)
Restructuring	509		0.7	—		—
Earnings before provision for taxes on income	19,196		27.4	20,563		27.7	(6.6)
Provision for taxes on income	3,787		5.4	4,240		5.7	(10.7)
Net earnings	$ 15,409		22.0	$ 16,323		22.0	(5.6)

Net earnings per share (Diluted)	$ 5.48			$ 5.70			(3.9)

Average shares outstanding (Diluted)	2,812.9			2,863.9

Effective tax rate	19.7	%		20.6	%

Adjusted earnings before provision for taxes and net earnings ^{(1) (A)}
Earnings before provision for taxes on income	$ 22,003		31.4	$ 22,825		30.7	(3.6)
Net earnings	$ 17,445		24.9	$ 18,318		24.6	(4.8)
Net earnings per share (Diluted)	$ 6.20			$ 6.39			(3.0)
Effective tax rate	20.7	%		19.7	%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, the Ortho-Clinical Diagnostics divestiture, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	FOURTH QUARTER
			Percent Change
	2015	2014	Total		Operations	Currency
Sales to customers by
segment of business

Consumer
U.S.	$ 1,231	1,294	(4.9)	%	(4.9)	—
International	2,089	2,312	(9.6)		5.5	(15.1)
	3,320	3,606	(7.9)		1.8	(9.7)

Pharmaceutical
U.S.	4,910	4,356	12.7		12.7	—
International	3,154	3,643	(13.4)		(0.9)	(12.5)
	8,064	7,999	0.8		6.5	(5.7)

Medical Devices
U.S.	3,152	2,954	6.7		6.7	—
International	3,275	3,695	(11.4)		0.6	(12.0)
	6,427	6,649	(3.3)		3.4	(6.7)

U.S.	9,293	8,604	8.0		8.0	—
International	8,518	9,650	(11.7)		1.2	(12.9)
Worldwide	$ 17,811	18,254	(2.4)	%	4.4	(6.8)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	TWELVE MONTHS
			Percent Change
	2015	2014	Total		Operations	Currency
Sales to customers by
segment of business

Consumer
U.S.	$ 5,222	5,096	2.5	%	2.5	—
International	8,285	9,400	(11.9)		2.7	(14.6)
	13,507	14,496	(6.8)		2.7	(9.5)

Pharmaceutical
U.S.	18,333	17,432	5.2		5.2	—
International	13,097	14,881	(12.0)		3.0	(15.0)
	31,430	32,313	(2.7)		4.2	(6.9)

Medical Devices
U.S.	12,132	12,254	(1.0)		(1.0)	—
International	13,005	15,268	(14.8)		(1.7)	(13.1)
	25,137	27,522	(8.7)		(1.4)	(7.3)

U.S.	35,687	34,782	2.6		2.6	—
International	34,387	39,549	(13.1)		1.1	(14.2)
Worldwide	$ 70,074	74,331	(5.7)	%	1.8	(7.5)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	FOURTH QUARTER
			Percent Change
	2015	2014	Total		Operations	Currency
Sales to customers by
geographic area

U.S.	$ 9,293	8,604	8.0	%	8.0	—

Europe	4,002	4,560	(12.2)		0.8	(13.0)
Western Hemisphere excluding U.S.	1,442	1,782	(19.1)		2.8	(21.9)
Asia-Pacific, Africa	3,074	3,308	(7.1)		0.9	(8.0)
International	8,518	9,650	(11.7)		1.2	(12.9)

Worldwide	$ 17,811	18,254	(2.4)	%	4.4	(6.8)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	TWELVE MONTHS
			Percent Change
	2015	2014	Total		Operations	Currency
Sales to customers by
geographic area

U.S.	$ 35,687	34,782	2.6	%	2.6	—

Europe	15,995	18,947	(15.6)		1.1	(16.7)
Western Hemisphere excluding U.S.	6,045	7,160	(15.6)		2.6	(18.2)
Asia-Pacific, Africa	12,347	13,442	(8.1)		0.3	(8.4)
International	34,387	39,549	(13.1)		1.1	(14.2)

Worldwide	$ 70,074	74,331	(5.7)	%	1.8	(7.5)



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
	Fourth Quarter		% Incr. /
(Dollars in Millions Except Per Share Data)	2015	2014	(Decr.)

Earnings before provision for taxes on income - as reported	$ 3,758	2,703	39.0	%

Intangible asset amortization expense	301	371

Restructuring⁽¹⁾	590	—

In-process research and development	214	156

Synthes integration costs	83	325

DePuy ASR^TM Hip program	—	—

Litigation expense, net	—	692

Ortho-Clinical Diagnostics divestiture net (gain)/expense	(33)	49

Additional year of Branded Prescription Drug Fee	—	—

Earnings before provision for taxes on income - as adjusted	$ 4,913	4,296	14.4	%

Net Earnings - as reported	$ 3,215	2,521	27.5	%

Intangible asset amortization expense	220	275

Restructuring	415	—

In-process research and development	156	115

Synthes integration costs	59	237

DePuy ASR^TM Hip program	—	—

Litigation expense, net	—	652

Ortho-Clinical Diagnostics divestiture net (gain)/expense	(22)	87

Additional year of Branded Prescription Drug Fee	—	—

Tax benefit associated with Conor Medsystems	—	—

Net Earnings - as adjusted	$ 4,043	3,887	4.0	%

Diluted Net Earnings per share - as reported	$ 1.15	0.89	29.2	%

Intangible asset amortization expense	0.07	0.10

Restructuring	0.15	—

In-process research and development	0.06	0.04

Synthes integration costs	0.02	0.08

DePuy ASR^TM Hip program	—	—

Litigation expense, net	—	0.23

Ortho-Clinical Diagnostics divestiture net (gain)/expense	(0.01)	0.03

Additional year of Branded Prescription Drug Fee	—	—

Tax benefit associated with Conor Medsystems	—	—

Diluted Net Earnings per share - as adjusted	$ 1.44	1.37	5.1	%

Operational Diluted Net Earnings per share - as adjusted*	$ 1.54	1.37	12.4	%

*Excludes the effect of translational currency

⁽¹⁾ Includes $81 million recorded in cost of products sold



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
	Twelve Months			% Incr. /
(Dollars in Millions Except Per Share Data)	2015	2014		(Decr.)

Earnings before provision for taxes on income - as reported	$ 19,196	20,563		(6.6)	%

Intangible asset amortization expense	1,570	1,630

Restructuring⁽¹⁾	590	—

In-process research and development	224	178

Synthes integration costs	196	754

DePuy ASR^TM Hip program	148	126

Litigation expense, net	141	1,253

Ortho-Clinical Diagnostics divestiture net (gain)/expense	(62)	(1,899)

Additional year of Branded Prescription Drug Fee	—	220

Earnings before provision for taxes on income - as adjusted	$ 22,003	22,825		(3.6)	%

Net Earnings - as reported	$ 15,409	16,323		(5.6)	%

Intangible asset amortization expense	1,113	1,213

Restructuring	415	—

In-process research and development	162	131

Synthes integration costs	144	555

DePuy ASR^TM Hip program	130	111

Litigation expense, net	118	1,225	⁽²⁾

Ortho-Clinical Diagnostics divestiture net (gain)/expense	(46)	(1,062)

Additional year of Branded Prescription Drug Fee	—	220

Tax benefit associated with Conor Medsystems	—	(398)

Net Earnings - as adjusted	$ 17,445	18,318		(4.8)	%

Diluted Net Earnings per share - as reported	$ 5.48	5.70		(3.9)	%

Intangible asset amortization expense	0.39	0.42

Restructuring	0.15	—

In-process research and development	0.06	0.04

Synthes integration costs	0.05	0.19

DePuy ASR^TM Hip program	0.05	0.04

Litigation expense, net	0.04	0.43

Ortho-Clinical Diagnostics divestiture net (gain)/expense	(0.02)	(0.37)

Additional year of Branded Prescription Drug Fee	—	0.08

Tax benefit associated with Conor Medsystems	—	(0.14)

Diluted Net Earnings per share - as adjusted	$ 6.20	6.39		(3.0)	%

Operational Diluted Net Earnings per share - as adjusted*	$ 6.76	6.39		5.8	%

*Excludes the effect of translational currency

⁽¹⁾ Includes $81 million recorded in cost of products sold
⁽²⁾ Includes adjustment to deferred tax asset related to deductibility by tax jurisdiction



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Operational Sales Growth Excluding Acquisitions, Divestitures and Hepatitis C Sales^{(1) (A)}
FOURTH QUARTER 2015 ACTUAL vs. 2014 ACTUAL

Segments
	Consumer	Pharmaceutical	Medical Devices	Total
	Operational %⁽²⁾
WW As Reported:	1.8%	6.5%	3.4%	4.4%
U.S.	(4.9)%	12.7%	6.7%	8.0%
International	5.5%	(0.9)%	0.6%	1.2%

Wound Care/Other
SPLENDA ^®	2.6			0.5
U.S.	6.5			1.0
International	0.3			0.1

Wound Care / Other
BENECOL ^®	0.3			0.1
U.S.	0.1			0.0
International	0.5			0.1

Diagnostics
Ortho-Clinical Diagnostics			(0.3)	(0.1)
U.S.			0.0	0.0
International			(0.5)	(0.2)

Cardiovascular
Cordis			2.6	0.9
U.S.			1.3	0.5
International			3.6	1.3

Other Neuroscience
NUCYNTA^®		0.5		0.2
U.S.		1.1		0.5
International		0.0		0.0

All Other Acquisitions and Divestitures			0.1	0.1
U.S.			0.0	0.0
International			0.2	0.1

WW Ops excluding Acquisitions and Divestitures	4.7%	7.0%	5.8%	6.1%
U.S.	1.7%	13.8%	8.0%	10.0%
International	6.3%	(0.9)%	3.9%	2.6%

Hepatitis C		4.1		1.7
U.S.		7.2		3.4
International		0.7		0.3

WW Ops excluding Hepatitis C only		10.6%		6.1%
U.S.		19.9%		11.4%
International		(0.2)%		1.5%

WW Ops excluding Acquisitions, Divestitures and Hepatitis C	4.7%	11.1%	5.8%	7.8%
U.S.	1.7%	21.0%	8.0%	13.4%
International	6.3%	(0.2)%	3.9%	2.9%

⁽¹⁾Hepatitis C products include OLYSIO ^® /SOVRIAD ^® and INCIVO^®
⁽²⁾ Operational growth excludes the effect of translational currency
^(A) NON-GAAP FINANCIAL MEASURE “Operational sales growth excluding the net impact of acquisitions, divestitures and hepatitis C sales” is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the magnitude of hepatitis C product sales over a short timeframe and the variable nature of acquisitions and divestitures and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Operational Sales Growth Excluding Acquisitions, Divestitures and Hepatitis C Sales^{(1) (A)}
TWELVE MONTHS 2015 ACTUAL vs. 2014 ACTUAL

Segments
	Consumer	Pharmaceutical	Medical Devices	Total
	Operational %⁽²⁾
WW As Reported:	2.7%	4.2%	(1.4)%	1.8%
U.S.	2.5%	5.2%	(1.0)%	2.6%
International	2.7%	3.0%	(1.7)%	1.1%

Wound Care/Other
SPLENDA ^®	0.6			0.1
U.S.	1.7			0.2
International	0.1			0.0

Women's Health
K-Y ^®	0.3			0.1
U.S.	0.4			0.1
International	0.2			0.0

Wound Care / Other
BENECOL ^®	0.6			0.1
U.S.	0.0			0.0
International	0.9			0.2

Diagnostics
Ortho-Clinical Diagnostics			3.2	1.2
U.S.			3.9	1.4
International			2.6	1.0

Cardiovascular
Cordis			0.6	0.3
U.S.			0.4	0.2
International			0.9	0.4

Other Neuroscience
NUCYNTA ^®		0.3		0.2
U.S.		0.6		0.3
International		0.0		0.0

All Other Acquisitions and Divestitures	(0.1)		0.1	0.0
U.S.	0.0		0.0	0.0
International	(0.1)		0.2	0.1

WW Ops excluding Acquisitions and Divestitures	4.1%	4.5%	2.5%	3.8%
U.S.	4.6%	5.8%	3.3%	4.8%
International	3.8%	3.0%	2.0%	2.8%

Hepatitis C		6.5		2.7
U.S.		12.3		5.8
International		0.3		0.2

WW Ops excluding Hepatitis C only		10.7%		4.5%
U.S.		17.5%		8.4%
International		3.3%		1.3%

WW Ops excluding Acquisitions, Divestitures and Hepatitis C	4.1%	11.0%	2.5%	6.5%
U.S.	4.6%	18.1%	3.3%	10.6%
International	3.8%	3.3%	2.0%	3.0%

⁽¹⁾ Hepatitis C products include OLYSIO ^® /SOVRIAD ^® and INCIVO ^®
⁽²⁾ Operational growth excludes the effect of translational currency
^(A) NON-GAAP FINANCIAL MEASURE “Operational sales growth excluding the net impact of acquisitions, divestitures and hepatitis C sales” is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the magnitude of hepatitis C product sales over a short timeframe and the variable nature of acquisitions and divestitures and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FOURTH QUARTER
				% Change
		2015	2014	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT⁽²⁾

BABY CARE
US	$	103	96	7.3	%	7.3	%	—	%
Intl		381	428	(11.0	)	2.8		(13.8	)
WW		484	524	(7.6	)	3.7		(11.3	)

ORAL CARE
US		170	150	13.3		13.3		—
Intl		238	264	(9.8	)	5.2		(15.0	)
WW		408	414	(1.4	)	8.2		(9.6	)

OTC
US		382	362	5.5		5.5		—
Intl		663	711	(6.8	)	9.4		(16.2	)
WW		1,045	1,073	(2.6	)	8.2		(10.8	)

SKIN CARE
US		439	471	(6.8	)	(6.8	)	—
Intl		432	485	(10.9	)	4.6		(15.5	)
WW		871	956	(8.9	)	(1.1	)	(7.8	)

WOMEN'S HEALTH
US		7	7	0.0		0.0		—
Intl		276	301	(8.3	)	7.5		(15.8	)
WW		283	308	(8.1	)	7.4		(15.5	)

WOUND CARE/OTHER
US		130	208	(37.5	)	(37.5	)	—
Intl		99	123	(19.5	)	(8.4	)	(11.1	)
WW		229	331	(30.8	)	(26.7	)	(4.1	)

TOTAL CONSUMER
US		1,231	1,294	(4.9	)	(4.9	)	—
Intl		2,089	2,312	(9.6	)	5.5		(15.1	)
WW	$	3,320	3,606	(7.9	)%	1.8	%	(9.7	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FOURTH QUARTER
				% Change
		2015	2014	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (3)}

IMMUNOLOGY
US	$	2,101	1,816	15.7	%	15.7	%	—	%
Intl		670	762	(12.1	)	2.0		(14.1	)
WW		2,771	2,578	7.5		11.7		(4.2	)
REMICADE
US		1,193	1,052	13.4		13.4		—
US Exports⁽⁴⁾		180	244	(26.2	)	(26.2	)	—
Intl		307	376	(18.4	)	(3.9	)	(14.5	)
WW		1,680	1,672	0.5		3.8		(3.3	)
SIMPONI / SIMPONI ARIA
US		204	164	24.4		24.4		—
Intl		136	182	(25.3	)	(14.8	)	(10.5	)
WW		340	346	(1.7	)	3.8		(5.5	)
STELARA
US		524	356	47.2		47.2		—
Intl		218	189	15.3		32.4		(17.1	)
WW		742	545	36.1		42.0		(5.9	)
OTHER IMMUNOLOGY
US		—	—	—		—		—
Intl		9	15	(40.0	)	(27.7	)	(12.3	)
WW		9	15	(40.0	)	(27.7	)	(12.3	)

INFECTIOUS DISEASES
US		363	564	(35.6	)	(35.6	)	—
Intl		438	512	(14.5	)	(3.6	)	(10.9	)
WW		801	1,076	(25.6	)	(20.4	)	(5.2	)
EDURANT
US		12	6	100.0		100.0		—
Intl		95	84	13.1		29.3		(16.2	)
WW		107	90	18.9		34.0		(15.1	)
OLYSIO / SOVRIAD
US		(1)	256	**		**		—
Intl		45	65	(30.8	)	(27.0	)	(3.8	)
WW		44	321	(86.3	)	(85.5	)	(0.8	)
PREZISTA / PREZCOBIX / REZOLSTA
US		287	243	18.1		18.1		—
Intl		180	205	(12.2	)	(0.2	)	(12.0	)
WW		467	448	4.2		9.7		(5.5	)
OTHER INFECTIOUS DISEASES
US		65	59	10.2		10.2		—
Intl		118	158	(25.3	)	(15.6	)	(9.7	)
WW		183	217	(15.7	)	(8.7	)	(7.0	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FOURTH QUARTER
				% Change
		2015	2014	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (3) (Continued)}

NEUROSCIENCE
US	$	752	645	16.6	%	16.6	%	—	%
Intl		849	1,006	(15.6	)	(4.2	)	(11.4	)
WW		1,601	1,651	(3.0	)	3.9		(6.9	)
CONCERTA / METHYLPHENIDATE
US		117	55	*		*		—
Intl		96	114	(15.8	)	(4.0	)	(11.8	)
WW		213	169	26.0		33.9		(7.9	)
INVEGA / PALIPERIDONE
US		58	96	(39.6	)	(39.6	)	—
Intl		55	65	(15.4	)	(5.6	)	(9.8	)
WW		113	161	(29.8	)	(25.9	)	(3.9	)
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA
US		327	226	44.7		44.7		—
Intl		197	192	2.6		17.7		(15.1	)
WW		524	418	25.4		32.4		(7.0	)
RISPERDAL CONSTA
US		103	104	(1.0	)	(1.0	)	—
Intl		131	190	(31.1	)	(21.2	)	(9.9	)
WW		234	294	(20.4	)	(14.0	)	(6.4	)
OTHER NEUROSCIENCE
US		147	164	(10.4	)	(10.4	)	—
Intl		370	445	(16.9	)	(6.3	)	(10.6	)
WW		517	609	(15.1	)	(7.4	)	(7.7	)

ONCOLOGY
US		457	334	36.8		36.8		—
Intl		816	878	(7.1	)	6.5		(13.6	)
WW		1,273	1,212	5.0		14.8		(9.8	)
IMBRUVICA
US		122	64	90.6		90.6		—
Intl		113	28	*		*		**
WW		235	92	*		*		**
VELCADE
US		—	—	—		—		—
Intl		321	418	(23.2	)	(13.5	)	(9.7	)
WW		321	418	(23.2	)	(13.5	)	(9.7	)
ZYTIGA
US		286	255	12.2		12.2		—
Intl		295	340	(13.2	)	0.2		(13.4	)
WW		581	595	(2.4	)	5.3		(7.7	)
OTHER ONCOLOGY
US		49	15	*		*		—
Intl		87	92	(5.4	)	10.3		(15.7	)
WW		136	107	27.1		40.5		(13.4	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FOURTH QUARTER
				% Change
		2015	2014	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (3) (Continued)}

CARDIOVASCULAR / METABOLISM / OTHER⁽⁵⁾
US	$	1,237	997	24.1	%	24.1	%	—	%
Intl		381	485	(21.4	)	(9.8	)	(11.6	)
WW		1,618	1,482	9.2		13.0		(3.8	)
XARELTO
US		494	428	15.4		15.4		—
Intl		—	—	—		—		—
WW		494	428	15.4		15.4		—
INVOKANA / INVOKAMET
US		348	193	80.3		80.3		—
Intl		24	8	*		*		**
WW		372	201	85.1		87.1		(2.0	)
PROCRIT / EPREX
US		173	177	(2.3	)	(2.3	)	—
Intl		87	125	(30.4	)	(20.0	)	(10.4	)
WW		260	302	(13.9	)	(9.6	)	(4.3	)
OTHER
US		222	199	11.6		11.6		—
Intl		270	352	(23.3	)	(12.1	)	(11.2	)
WW		492	551	(10.7	)	(3.5	)	(7.2	)

TOTAL PHARMACEUTICAL
US		4,910	4,356	12.7		12.7		—
Intl		3,154	3,643	(13.4	)	(0.9	)	(12.5	)
WW	$	8,064	7,999	0.8	%	6.5	%	(5.7	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FOURTH QUARTER
				% Change
		2015	2014	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES ^{(2) (3)}

CARDIOVASCULAR
US	$	229	222	3.2	%	3.2	%	—	%
Intl		210	336	(37.5	)	(29.4	)	(8.1	)
WW		439	558	(21.3	)	(16.4	)	(4.9	)

DIABETES CARE
US		202	206	(1.9	)	(1.9	)	—
Intl		278	308	(9.7	)	5.0		(14.7	)
WW		480	514	(6.6	)	2.2		(8.8	)

DIAGNOSTICS⁽⁶⁾
US		—	—	—		—		—
Intl		24	14	71.4		**		**
WW		24	14	71.4		**		**

ORTHOPAEDICS
US		1,438	1,339	7.4		7.4		—
Intl		985	1,102	(10.6	)	1.0		(11.6	)
WW		2,423	2,441	(0.7	)	4.5		(5.2	)

HIPS
US		213	194	9.8		9.8		—
Intl		141	156	(9.6	)	2.3		(11.9	)
WW		354	350	1.1		6.4		(5.3	)

KNEES
US		254	236	7.6		7.6		—
Intl		151	165	(8.5	)	2.4		(10.9	)
WW		405	401	1.0		5.5		(4.5	)

TRAUMA
US		379	352	7.7		7.7		—
Intl		265	287	(7.7	)	4.6		(12.3	)
WW		644	639	0.8		6.3		(5.5	)

SPINE & OTHER
US		592	557	6.3		6.3		—
Intl		428	494	(13.4	)	(2.1	)	(11.3	)
WW		1,020	1,051	(2.9	)	2.4		(5.3	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FOURTH QUARTER
				% Change
		2015	2014	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES ^{(2) (3) (Continued)}

SURGERY
US	$	1,044	992	5.2	%	5.2	%	—
Intl		1,369	1,484	(7.7	)	4.4		(12.1	)
WW		2,413	2,476	(2.5	)	4.7		(7.2	)

ADVANCED
US		384	352	9.1		9.1		—
Intl		486	497	(2.2	)	10.1		(12.3	)
WW		870	849	2.5		9.7		(7.2	)

GENERAL
US		430	432	(0.5	)	(0.5	)	—
Intl		717	821	(12.7	)	(1.3	)	(11.4	)
WW		1,147	1,253	(8.5	)	(1.0	)	(7.5	)

SPECIALTY
US		230	208	10.6		10.6		—
Intl		166	166	0.0		14.6		(14.6	)
WW		396	374	5.9		12.4		(6.5	)

VISION CARE
US		239	195	22.6		22.6		—
Intl		409	451	(9.3	)	2.3		(11.6	)
WW		648	646	0.3		8.4		(8.1	)

TOTAL MEDICAL DEVICES
US		3,152	2,954	6.7		6.7		—
Intl		3,275	3,695	(11.4	)	0.6		(12.0	)
WW	$	6,427	6,649	(3.3	)%	3.4	%	(6.7	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		TWELVE MONTHS
				% Change
		2015	2014	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT⁽²⁾

BABY CARE
US	$	421	407	3.4	%	3.4	%	—	%
Intl		1,623	1,832	(11.4	)	0.7		(12.1	)
WW		2,044	2,239	(8.7	)	1.2		(9.9	)

ORAL CARE
US		629	600	4.8		4.8		—
Intl		951	1,047	(9.2	)	5.5		(14.7	)
WW		1,580	1,647	(4.1	)	5.2		(9.3	)

OTC
US		1,536	1,357	13.2		13.2		—
Intl		2,439	2,749	(11.3	)	5.5		(16.8	)
WW		3,975	4,106	(3.2	)	8.1		(11.3	)

SKIN CARE
US		1,857	1,834	1.3		1.3		—
Intl		1,674	1,924	(13.0	)	1.2		(14.2	)
WW		3,531	3,758	(6.0	)	1.3		(7.3	)

WOMEN'S HEALTH
US		26	50	(48.0	)	(48.0	)	—
Intl		1,174	1,252	(6.2	)	9.8		(16.0	)
WW		1,200	1,302	(7.8	)	7.6		(15.4	)

WOUND CARE/OTHER
US		753	848	(11.2	)	(11.2	)	—
Intl		424	596	(28.9	)	(18.3	)	(10.6	)
WW		1,177	1,444	(18.5	)	(14.1	)	(4.4	)

TOTAL CONSUMER
US		5,222	5,096	2.5		2.5		—
Intl		8,285	9,400	(11.9	)	2.7		(14.6	)
WW	$	13,507	14,496	(6.8	)%	2.7	%	(9.5	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		TWELVE MONTHS
				% Change
		2015	2014	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (3)}

IMMUNOLOGY
US	$	7,642	7,111	7.5	%	7.5	%	—	%
Intl		2,760	3,082	(10.4	)	5.5		(15.9	)
WW		10,402	10,193	2.1		6.9		(4.8	)
REMICADE
US		4,453	4,155	7.2		7.2		—
US Exports⁽⁴⁾		782	1,078	(27.5	)	(27.5	)	—
Intl		1,326	1,635	(18.9	)	(4.7	)	(14.2	)
WW		6,561	6,868	(4.5	)	(1.1	)	(3.4	)
SIMPONI / SIMPONI ARIA
US		730	544	34.2		34.2		—
Intl		598	643	(7.0	)	10.2		(17.2	)
WW		1,328	1,187	11.9		21.2		(9.3	)
STELARA
US		1,677	1,334	25.7		25.7		—
Intl		797	738	8.0		27.0		(19.0	)
WW		2,474	2,072	19.4		26.2		(6.8	)
OTHER IMMUNOLOGY
US		—	—	—		—		—
Intl		39	66	(40.9	)	(30.6	)	(10.3	)
WW		39	66	(40.9	)	(30.6	)	(10.3	)

INFECTIOUS DISEASES
US		1,535	3,112	(50.7	)	(50.7	)	—
Intl		2,121	2,487	(14.7	)	1.2		(15.9	)
WW		3,656	5,599	(34.7	)	(27.6	)	(7.1	)
EDURANT
US		41	24	70.8		70.8		—
Intl		369	341	8.2		29.2		(21.0	)
WW		410	365	12.3		31.9		(19.6	)
OLYSIO / SOVRIAD
US		173	1,943	(91.1	)	(91.1	)	—
Intl		448	359	24.8		49.1		(24.3	)
WW		621	2,302	(73.0	)	(69.2	)	(3.8	)
PREZISTA / PREZCOBIX / REZOLSTA
US		1,064	930	14.4		14.4		—
Intl		746	901	(17.2	)	(1.6	)	(15.6	)
WW		1,810	1,831	(1.1	)	6.6		(7.7	)
OTHER INFECTIOUS DISEASES
US		257	215	19.5		19.5		—
Intl		558	886	(37.0	)	(26.2	)	(10.8	)
WW		815	1,101	(26.0	)	(17.3	)	(8.7	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		TWELVE MONTHS
				% Change
		2015	2014	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (3) (Continued)}

NEUROSCIENCE
US	$	2,850	2,452	16.2	%	16.2	%	—	%
Intl		3,409	4,035	(15.5	)	(1.8	)	(13.7	)
WW		6,259	6,487	(3.5	)	5.0		(8.5	)
CONCERTA / METHYLPHENIDATE
US		434	152	*		*		—
Intl		387	447	(13.4	)	(0.3	)	(13.1	)
WW		821	599	37.1		46.9		(9.8	)
INVEGA / PALIPERIDONE
US		339	360	(5.8	)	(5.8	)	—
Intl		234	280	(16.4	)	(2.9	)	(13.5	)
WW		573	640	(10.5	)	(4.6	)	(5.9	)
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA
US		1,085	825	31.5		31.5		—
Intl		745	763	(2.4	)	14.9		(17.3	)
WW		1,830	1,588	15.2		23.5		(8.3	)
RISPERDAL CONSTA
US		409	427	(4.2	)	(4.2	)	—
Intl		561	763	(26.5	)	(12.9	)	(13.6	)
WW		970	1,190	(18.5	)	(9.8	)	(8.7	)
OTHER NEUROSCIENCE
US		583	688	(15.3	)	(15.3	)	—
Intl		1,482	1,782	(16.8	)	(4.5	)	(12.3	)
WW		2,065	2,470	(16.4	)	(7.5	)	(8.9	)

ONCOLOGY
US		1,547	1,157	33.7		33.7		—
Intl		3,148	3,300	(4.6	)	12.2		(16.8	)
WW		4,695	4,457	5.3		17.7		(12.4	)
IMBRUVICA
US		375	145	*		*		—
Intl		314	55	*		*		**
WW		689	200	*		*		**
VELCADE
US		—	—	—		—		—
Intl		1,333	1,618	(17.6	)	(4.2	)	(13.4	)
WW		1,333	1,618	(17.6	)	(4.2	)	(13.4	)
ZYTIGA
US		1,070	971	10.2		10.2		—
Intl		1,161	1,266	(8.3	)	9.0		(17.3	)
WW		2,231	2,237	(0.3	)	9.5		(9.8	)
OTHER ONCOLOGY
US		102	41	*		*		—
Intl		340	361	(5.8	)	11.2		(17.0	)
WW		442	402	10.0		25.2		(15.2	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		TWELVE MONTHS
				% Change
		2015	2014	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (3) (Continued)}

CARDIOVASCULAR / METABOLISM / OTHER⁽⁵⁾
US	$	4,759	3,600	32.2	%	32.2	%	—	%
Intl		1,659	1,977	(16.1	)	(3.9	)	(12.2	)
WW		6,418	5,577	15.1		19.4		(4.3	)
XARELTO
US		1,868	1,522	22.7		22.7		—
Intl		—	—	—		—		—
WW		1,868	1,522	22.7		22.7		—
INVOKANA / INVOKAMET
US		1,238	569	*		*		—
Intl		70	17	*		*		**
WW		1,308	586	*		*		**
PROCRIT / EPREX
US		692	715	(3.2	)	(3.2	)	—
Intl		376	523	(28.1	)	(15.8	)	(12.3	)
WW		1,068	1,238	(13.7	)	(8.5	)	(5.2	)
OTHER
US		961	794	21.0		21.0		—
Intl		1,213	1,437	(15.6	)	(4.1	)	(11.5	)
WW		2,174	2,231	(2.6	)	4.8		(7.4	)

TOTAL PHARMACEUTICAL
US		18,333	17,432	5.2		5.2		—
Intl		13,097	14,881	(12.0	)	3.0		(15.0	)
WW	$	31,430	32,313	(2.7	)%	4.2	%	(6.9	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		TWELVE MONTHS
				% Change
		2015	2014	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES ^{(2) (3)}

CARDIOVASCULAR
US	$	931	862	8.0	%	8.0	%	—	%
Intl		1,105	1,346	(17.9	)	(5.3	)	(12.6	)
WW		2,036	2,208	(7.8	)	(0.1	)	(7.7	)

DIABETES CARE
US		833	864	(3.6	)	(3.6	)	—
Intl		1,095	1,278	(14.3	)	1.3		(15.6	)
WW		1,928	2,142	(10.0	)	(0.7	)	(9.3	)

DIAGNOSTICS⁽⁶⁾
US		—	456	**		**		—
Intl		86	506	(83.0	)	**		**
WW		86	962	(91.1	)	**		**

ORTHOPAEDICS
US		5,380	5,197	3.5		3.5		—
Intl		3,882	4,478	(13.3	)	(0.3	)	(13.0	)
WW		9,262	9,675	(4.3	)	1.7		(6.0	)

HIPS
US		781	745	4.8		4.8		—
Intl		551	623	(11.6	)	1.1		(12.7	)
WW		1,332	1,368	(2.6	)	3.2		(5.8	)

KNEES
US		916	878	4.3		4.3		—
Intl		580	655	(11.5	)	0.7		(12.2	)
WW		1,496	1,533	(2.4	)	2.8		(5.2	)

TRAUMA
US		1,462	1,418	3.1		3.1		—
Intl		1,066	1,222	(12.8	)	0.6		(13.4	)
WW		2,528	2,640	(4.2	)	2.0		(6.2	)

SPINE & OTHER
US		2,221	2,156	3.0		3.0		—
Intl		1,685	1,978	(14.8	)	(1.8	)	(13.0	)
WW		3,906	4,134	(5.5	)	0.7		(6.2	)



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		TWELVE MONTHS
				% Change
		2015	2014	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES ^{(2) (3) (Continued)}

SURGERY
US	$	3,991	3,900	2.3	%	2.3	%	—	%
Intl		5,226	5,817	(10.2	)	2.9		(13.1	)
WW		9,217	9,717	(5.1	)	2.7		(7.8	)

ADVANCED
US		1,430	1,342	6.6		6.6		—
Intl		1,845	1,895	(2.6	)	10.8		(13.4	)
WW		3,275	3,237	1.2		9.1		(7.9	)

GENERAL
US		1,702	1,717	(0.9	)	(0.9	)	—
Intl		2,780	3,253	(14.5	)	(1.9	)	(12.6	)
WW		4,482	4,970	(9.8	)	(1.5	)	(8.3	)

SPECIALTY
US		859	841	2.1		2.1		—
Intl		601	669	(10.2	)	4.3		(14.5	)
WW		1,460	1,510	(3.3	)	3.1		(6.4	)

VISION CARE
US		997	975	2.3		2.3		—
Intl		1,611	1,843	(12.6	)	1.5		(14.1	)
WW		2,608	2,818	(7.5	)	1.7		(9.2	)

TOTAL MEDICAL DEVICES
US		12,132	12,254	(1.0	)	(1.0	)	—
Intl		13,005	15,268	(14.8	)	(1.7	)	(13.1	)
WW	$	25,137	27,522	(8.7	)%	(1.4	)%	(7.3	)%

* Percentage greater than 100%
** Not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Prior year amounts have been reclassified to conform to current year product disclosure
(4) Reported as U.S. sales
(5) Previously referred to as Other
(6) Reflects Diagnostics divestiture June 30, 2014

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

JNJ Johnson and Johnson

Latest JNJ Messages

Loading Messages....

Johnson & Johnson News

Loading Messages....

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

JNJ Johnson and Johnson

Latest JNJ Messages

Loading Messages....

Johnson & Johnson News

Loading Messages....

Your Recent History

Company

Business

Popular

Get The App